Shefali Luthra

Heart Drug Spotlights Troubling Trends In Drug Marketing

A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.

Once Its Greatest Foes, Doctors Are Embracing Single-Payer

A shift is occurring, with many younger physicians concerned more about social justice than profit.

When the American Medical Association — one of the nation’s most powerful health care groups — met in Chicago this June, its medical student caucus seized an opportunity for change.

Subscribe to Shefali Luthra